Related Experiment Video
Updated: Jun 24, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results
Klaas P Koopmans1, Oliver N Neels, Ido P Kema
1Department of Nuclear Medicine and Molecular Imaging, University of Groningen and University Medical Centre Groningen, 9700 RB Groningen, The Netherlands.
Abstract:
Neuroendocrine tumors can originate almost everywhere in the body and consist of a great variety of subtypes. This paper focuses on molecular imaging methods using nuclear medicine techniques in neuroendocrine tumors, coupling molecular uptake mechanisms of radiotracers with clinical results. A non-systematic review is presented on receptor based and metabolic imaging methods. Receptor-based imaging covers the molecular backgrounds of somatostatin, vaso-intestinal peptide (VIP), bombesin and cholecystokinin (CCK) receptors and their link with nuclear imaging. Imaging methods based on specific metabolic properties include meta-iodo-benzylguanide (MIBG) and dimercapto-sulphuric acid (DMSA-V) scintigraphy as well as more modern positron emission tomography (PET)-based methods using radio-labeled analogues of amino acids, glucose, dihydroxyphenylalanine (DOPA), dopamine and tryptophan. Diagnostic sensitivities are presented for each imaging method and for each neuroendocrine tumor subtype. Finally, a Forest plot analysis of diagnostic performance is presented for each tumor type in order to provide a comprehensive overview for clinical use.
Insights
This review explores nuclear medicine imaging for neuroendocrine tumors (NETs), detailing receptor-based and metabolic techniques. It highlights diagnostic sensitivities and performance for various NET subtypes, aiding clinical decisions.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiochemistry
Background:
- Neuroendocrine tumors (NETs) are diverse and can arise throughout the body.
- Accurate diagnosis and staging of NETs are crucial for effective treatment planning.
- Molecular imaging plays a vital role in visualizing NETs and understanding their behavior.
Purpose of the Study:
- To review molecular imaging methods for neuroendocrine tumors (NETs) using nuclear medicine.
- To correlate radiotracer uptake mechanisms with clinical outcomes.
- To provide a comprehensive overview of diagnostic performance for various NET subtypes.
Main Methods:
- Non-systematic review of receptor-based imaging (somatostatin, VIP, bombesin, CCK receptors).
- Review of metabolic imaging (MIBG, DMSA-V scintigraphy, PET-based methods using amino acids, glucose, DOPA, dopamine, tryptophan).
- Presentation of diagnostic sensitivities and Forest plot analysis for performance evaluation.
Main Results:
- Detailed diagnostic sensitivities for each imaging method across different NET subtypes.
- Comparison of receptor-based versus metabolic imaging approaches.
- Forest plot analysis summarizing diagnostic performance for clinical utility.
Conclusions:
- Nuclear medicine offers a range of molecular imaging techniques for NET diagnosis.
- Receptor-based and metabolic imaging provide complementary information for NET management.
- This review offers a clinical overview to guide the selection of appropriate imaging modalities for NETs.
